Market Place
Sourcing Support
AB Science Secures European Patent for Masitinib in Sickle Cell
28 Oct 2024 //
#N/A
AB Science Updates Application For Masitinib In ALS
17 Oct 2024 //
GLOBENEWSWIRE
AB Sciences H1 2024 Revenues And Activities Update on activities
10 Oct 2024 //
GLOBENEWSWIRE
AB Science Delays Publication Of 2024 Half-Year Financial Report
30 Sep 2024 //
GLOBENEWSWIRE
AB Science Updates On AB8939 Microtubule Program
26 Sep 2024 //
GLOBENEWSWIRE
AB Science Updates On Masitinib In Multiple Sclerosis
23 Sep 2024 //
GLOBENEWSWIRE
AB Science announces results of Phase 2 study evaluating masitinib in Covid-19
08 Jul 2024 //
GLOBENEWSWIRE
AB Science Updates On Masitinib Application For ALS
28 Jun 2024 //
GLOBENEWSWIRE
AB Science Updates On Masitinib Conditional Marketing Application In ALS
31 May 2024 //
GLOBENEWSWIRE
AB Science Updates On Masitinib Application For ALS Approval
29 May 2024 //
GLOBENEWSWIRE
AB Science Reports 2023 Revenues, Activity Update
15 May 2024 //
GLOBENEWSWIRE
AB Science Masitinib EU Patent To 2036 In Mastocytosis
13 May 2024 //
GLOBENEWSWIRE
AB Science: Data Supports ALSFR-S Rate in ALS Studies & Treatment Choice
06 May 2024 //
GLOBENEWSWIRE
Paris Court Acquits AB Science CEO, Reduces Fine On AB Science
02 May 2024 //
GLOBENEWSWIRE
AB Science Delays Publishing 2023 Annual Financial Report
30 Apr 2024 //
GLOBENEWSWIRE
AB Announces that HC has Granted Eligibility for Reconsideration for Masitinib
03 Apr 2024 //
GLOBENEWSWIRE
AB Science: New research shows that masitinib limits neuronal damage
13 Mar 2024 //
GLOBENEWSWIRE
AB Science provides a summary of the live webcast held on March 4, 2024
07 Mar 2024 //
GLOBENEWSWIRE
AB Science announces that firms have initiated coverage of the Company
06 Mar 2024 //
GLOBENEWSWIRE
AB Science will host webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
01 Mar 2024 //
GLOBENEWSWIRE
AB Science will host webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
29 Feb 2024 //
GLOBENEWSWIRE
AB Science announces that Health Canada has issued a NON/w for masitinib
26 Feb 2024 //
GLOBENEWSWIRE
AB Science announces an update in the MAA of masitinib
26 Jan 2024 //
GLOBENEWSWIRE
AB Science receives notice of allowance for European patent covering masitinib
15 Jan 2024 //
GLOBENEWSWIRE
AB Science will host a live webcast on Thursday November 30, 2023
28 Nov 2023 //
GLOBENEWSWIRE
AB Science: The development of masitinib is among the 19 winning projects
27 Nov 2023 //
GLOBENEWSWIRE
AB Science today reports its revenues for the first half of 2023
29 Sep 2023 //
GLOBENEWSWIRE
AB Science provides an update on the EMA examination of masitinib MAA
18 Sep 2023 //
GLOBENEWSWIRE
AB Science receives Notice of Allowance for European patent covering masitinib
26 Jun 2023 //
GLOBENEWSWIRE
AB Science announces issuance of a Canadian patent for masitinib
01 Jun 2023 //
GLOBENEWSWIRE
AB Science summarizes key messages from its participation at 2023 Summit
17 May 2023 //
GLOBENEWSWIRE
AB Science announces that Health Canada has resumed review of NDA for masitinib
09 May 2023 //
GLOBENEWSWIRE
Summary of the presentation on masitinib in ALS delivered at 2023
27 Apr 2023 //
GLOBENEWSWIRE
AB Science announces the success of its capital increase by private placemen
24 Apr 2023 //
GLOBENEWSWIRE
AB Science announces the implementation strategy &launch of a capital increase
21 Apr 2023 //
GLOBENEWSWIRE
AB Science announces masitinib patent granted in Japan for the treatment ofALS
18 Apr 2023 //
GLOBENEWSWIRE
AB Science: Results of masitinib for a scientific platform presentation at AAN
12 Apr 2023 //
GLOBENEWSWIRE
AB Science will host a live webcast on its MDA platform
15 Mar 2023 //
GLOBENEWSWIRE
AB Science reports a first complete bone marrow response in a acute myeloid leukemia patient
13 Mar 2023 //
GLOBENEWSWIRE
AB Science announced publication of the masitinib pivotal PIII trial in journal
28 Feb 2023 //
GLOBENEWSWIRE
AB Science announces the drawdown of the second tranche of 6 million euros
31 Jan 2023 //
GLOBENEWSWIRE
AB Science has received approval from the USFDA for Ph3 study with masitinib
30 Dec 2022 //
GLOBENEWSWIRE
Masitinib receives orphan drug status for the treatment of ALS in Switzerland
27 Dec 2022 //
GLOBENEWSWIRE
AB Science announces the drawdown of the first tranche of 6 million euros
22 Dec 2022 //
GLOBENEWSWIRE
AB Science receives NOD from Health Canada for masitinib in the treatment of ALS
13 Dec 2022 //
GLOBENEWSWIRE
AB Science receives FDA authorization to initiate Phase 3 study with masitinib
21 Nov 2022 //
GLOBENEWSWIRE
AB Science receives first agencies authorizations Ph3 clinical study masitinib
10 Oct 2022 //
GLOBENEWSWIRE
AB Science today reports its revenues for the first half of 2022
30 Sep 2022 //
GLOBENEWSWIRE
AB Science - Positive recommendation of the Data and Safety Monitoring
14 Sep 2022 //
GLOBENEWSWIRE
AB Science has filed an application for CMA to EMA for masitinib
24 Aug 2022 //
GLOBENEWSWIRE
AB Science announced publication of results from its positive study of masitinib
07 Jun 2022 //
GLOBENEWSWIRE
AB Science announces that Health Canada has started the review of masitinib
26 May 2022 //
GLOBENEWSWIRE
AB Science reports its revenues for the year 2021
29 Apr 2022 //
GLOBENEWSWIRE
AB Science continues PII study evaluating masitinib + isoquercetin
28 Apr 2022 //
GLOBENEWSWIRE
AB Science following the decision of the Enforcement Committee of AMF
29 Mar 2022 //
GLOBENEWSWIRE
AB Science announces financing of a $8.5M through convertible bonds
28 Feb 2022 //
GLOBENEWSWIRE
AB Science will host a live webcast on the masitinib filing
24 Feb 2022 //
GLOBENEWSWIRE
AB Science announces publication of masitinib positive pivotal Phase 3 trial
22 Feb 2022 //
GLOBENEWSWIRE
Health Canada grants AB Science authorization to file NDS for masitinib in ALS
21 Feb 2022 //
GLOBENEWSWIRE
